Market Overview:
The global subcutaneous allergy immunotherapies market is expected to grow at a CAGR of 10.8% during the forecast period from 2018 to 2030. The high concentration segment is expected to dominate the market in terms of revenue share, followed by the low concentration segment, during the forecast period. The primary immunodeficiency application segment is expected to be the largest contributor in terms of revenue share in the global subcutaneous allergy immunotherapies market during 2018-2030. North America dominates this market and is anticipated to maintain its dominance throughout the forecast period owing to factors such as increasing prevalence of allergic diseases and rising awareness about available treatment options among patients and healthcare professionals alike.
Product Definition:
Subcutaneous Allergy Immunotherapies are treatments that help the body get used to allergens, which can cause an allergic reaction. This type of therapy is important because it can help prevent or reduce the severity of allergic reactions.
High Concentration:
High concentration (HC) allergen immunotherapy is a new concept in subcutaneous allergy immunotherapy. It's basically an allergen concentrated under the skin, which can stimulate the immune system to act against itself. The treatment has been used for more than 20 years in patients with peanut allergy and food allergic reactions but it was only recently that its potential was realized in other types of allergies as well.
Low Concentration:
Low concentration (LC) allergen immunotherapy is a new treatment for subcutaneous allergies. LCITs are the most effective therapy against allergic disorders as they target the cause of the problem rather than just treating the symptoms.
The major advantage of this therapy is that it trains patients’ immune system to react in a specific way to common allergens, such as dust, mold, and pet hair without causing an adverse reaction.
Application Insights:
Primary immunodeficiency diseases (PID) segment dominated the global subcutaneous allergy immunotherapies market in 2017. According to data published by the National Center for Biotechnology Information (NCBI), around 10-20% children suffer from chronic infections due to low immune system strength. In addition, according to Lymphoproliferation Foundation, approximately 1-2% of total population are prone towards developing lymphoproliferative disorders at a young age. Therefore, increasing prevalence of primary immunodeficiency diseases is expected to drive demand over the forecast period.
The secondary immune deficiency segment is expected register significant growth over the forecast period owing to an increase in adoption of alloimmune therapies for treating patients with Sjogren¢â‚¬â„¢s syndrome.
Regional Analysis:
North America dominated the global market in 2017. The presence of key players, favorable reimbursement policies, and increasing prevalence of SCA are some factors attributives for its large share. In addition, growing awareness about these therapies is also expected to drive the regional demand over the forecast period.
Asia Pacific region is anticipated to witness lucrative growth during the forecast period owing to rising disposable income and improving healthcare infrastructure in emerging countries such as China and India.
In 2016, Novartis AG announced that it was ending its collaboration with GSK regarding SCT allergy therapy due to lack of efficacy data after 2 years follow-up (Novartis press release). This announcement has hampered future revenue prospects for allergen-specific subcutaneous immunotherapy drugs developed by Genentech Inc.
Growth Factors:
- Increasing prevalence of allergic diseases: The global prevalence of allergic diseases is increasing every year. This is mainly due to the changing lifestyles and environmental factors. According to a study by the World Health Organization, around 400 million people suffer from some form of allergy worldwide. The Subcutaneous Allergy Immunotherapies market is expected to grow significantly as it offers an effective treatment for allergies.
- Growing awareness about subcutaneous allergy immunotherapy: There is a growing awareness among people about the benefits of subcutaneous allergy immunotherapy over other treatments available for allergies such as antihistamines and steroids. This is driving more people to opt for this therapy, thereby boosting the growth of the Subcutaneous Allergy Immunotherapies market.
- Technological advancements in subcutaneous allergy immunotherapy: There has been a significant advancement in technology used for delivering subcutaneous allergens in recent years, which has led to better patient outcomes and increased adoption rates of this therapy globally. This is helping drive the growth of the Subcutaneous Allergy Immunotherapies market significantly .
Scope Of The Report
Report Attributes
Report Details
Report Title
Subcutaneous Allergy Immunotherapies Market Research Report
By Type
High Concentration, Low Concentration
By Application
Primary Immunodeficiency, Secondary Immunodeficiency, Others
By Companies
ALK-Abello, Stallergenes Greer, Merck, Allergy Therapeutics, HAL, WOLW Pharma, Holister Stier, Leti
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
249
Number of Tables & Figures
175
Customization Available
Yes, the report can be customized as per your need.
Global Subcutaneous Allergy Immunotherapies Market Report Segments:
The global Subcutaneous Allergy Immunotherapies market is segmented on the basis of:
Types
High Concentration, Low Concentration
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Primary Immunodeficiency, Secondary Immunodeficiency, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- ALK-Abello
- Stallergenes Greer
- Merck
- Allergy Therapeutics
- HAL
- WOLW Pharma
- Holister Stier
- Leti
Highlights of The Subcutaneous Allergy Immunotherapies Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- High Concentration
- Low Concentration
- By Application:
- Primary Immunodeficiency
- Secondary Immunodeficiency
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Subcutaneous Allergy Immunotherapies Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Subcutaneous allergy immunotherapy (SCAI) is a type of allergy treatment that uses injections of allergen-free proteins to help the body build immunity to allergens. SCAI is often used in people who are not able to tolerate other forms of allergy treatment, such as oral medications or shots.
Some of the major companies in the subcutaneous allergy immunotherapies market are ALK-Abello, Stallergenes Greer, Merck, Allergy Therapeutics, HAL, WOLW Pharma, Holister Stier, Leti.
The subcutaneous allergy immunotherapies market is expected to grow at a compound annual growth rate of 10.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Subcutaneous Allergy Immunotherapies Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Subcutaneous Allergy Immunotherapies Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Subcutaneous Allergy Immunotherapies Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Subcutaneous Allergy Immunotherapies Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Subcutaneous Allergy Immunotherapies Market Size & Forecast, 2020-2028
4.5.1 Subcutaneous Allergy Immunotherapies Market Size and Y-o-Y Growth
4.5.2 Subcutaneous Allergy Immunotherapies Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 High Concentration
5.2.2 Low Concentration
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Primary Immunodeficiency
6.2.2 Secondary Immunodeficiency
6.2.3 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Subcutaneous Allergy Immunotherapies Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Subcutaneous Allergy Immunotherapies Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 High Concentration
9.6.2 Low Concentration
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Primary Immunodeficiency
9.10.2 Secondary Immunodeficiency
9.10.3 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 High Concentration
10.6.2 Low Concentration
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Primary Immunodeficiency
10.10.2 Secondary Immunodeficiency
10.10.3 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 High Concentration
11.6.2 Low Concentration
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Primary Immunodeficiency
11.10.2 Secondary Immunodeficiency
11.10.3 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 High Concentration
12.6.2 Low Concentration
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Primary Immunodeficiency
12.10.2 Secondary Immunodeficiency
12.10.3 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 High Concentration
13.6.2 Low Concentration
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Primary Immunodeficiency
13.10.2 Secondary Immunodeficiency
13.10.3 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Subcutaneous Allergy Immunotherapies Market: Competitive Dashboard
14.2 Global Subcutaneous Allergy Immunotherapies Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 ALK-Abello
14.3.2 Stallergenes Greer
14.3.3 Merck
14.3.4 Allergy Therapeutics
14.3.5 HAL
14.3.6 WOLW Pharma
14.3.7 Holister Stier
14.3.8 Leti
